Cargando…
Discovery and Preclinical Work
In any drug discovery and development effort, we must accomplish a number of critical steps to arrive at a compound that is safe and efficacious, and also exhibits the complex array of desired drug-like behaviors that warrants advancement to the clinic. These tasks include target identification and...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177020/ http://dx.doi.org/10.1007/978-3-319-02201-7_2 |
_version_ | 1783525127317618688 |
---|---|
author | Mochly-Rosen, Daria Grimes, Kevin |
author_facet | Mochly-Rosen, Daria Grimes, Kevin |
author_sort | Mochly-Rosen, Daria |
collection | PubMed |
description | In any drug discovery and development effort, we must accomplish a number of critical steps to arrive at a compound that is safe and efficacious, and also exhibits the complex array of desired drug-like behaviors that warrants advancement to the clinic. These tasks include target identification and validation; screening for active compounds; chemical modification of candidate compounds to achieve optimized pharmacology; formulating the final drug product; and establishing safety in preclinical models. “Repurposing” drugs that have previously been approved (or shown to be safe in humans) for new clinical indications can provide a faster, less risky, and more cost-effective route for bringing a new therapy to patients. Such shortcuts in development can be particularly valuable to resource-constrained academicians. When performing drug discovery research, we must be particularly attentive to the robustness of our experiments, because inability to reproduce academic data continues to be a sticking point when projects are transferred to industry. Our experiments must be appropriately blinded, statistically powered, and meticulously documented so that our findings are worthy of the large investment required for their further translation into a drug. This chapter walks through the essential preclinical drug development steps that lead to a clinical drug candidate. |
format | Online Article Text |
id | pubmed-7177020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71770202020-04-23 Discovery and Preclinical Work Mochly-Rosen, Daria Grimes, Kevin A Practical Guide to Drug Development in Academia Article In any drug discovery and development effort, we must accomplish a number of critical steps to arrive at a compound that is safe and efficacious, and also exhibits the complex array of desired drug-like behaviors that warrants advancement to the clinic. These tasks include target identification and validation; screening for active compounds; chemical modification of candidate compounds to achieve optimized pharmacology; formulating the final drug product; and establishing safety in preclinical models. “Repurposing” drugs that have previously been approved (or shown to be safe in humans) for new clinical indications can provide a faster, less risky, and more cost-effective route for bringing a new therapy to patients. Such shortcuts in development can be particularly valuable to resource-constrained academicians. When performing drug discovery research, we must be particularly attentive to the robustness of our experiments, because inability to reproduce academic data continues to be a sticking point when projects are transferred to industry. Our experiments must be appropriately blinded, statistically powered, and meticulously documented so that our findings are worthy of the large investment required for their further translation into a drug. This chapter walks through the essential preclinical drug development steps that lead to a clinical drug candidate. 2013-09-23 /pmc/articles/PMC7177020/ http://dx.doi.org/10.1007/978-3-319-02201-7_2 Text en © Springer International Publishing Switzerland 2014 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Mochly-Rosen, Daria Grimes, Kevin Discovery and Preclinical Work |
title | Discovery and Preclinical Work |
title_full | Discovery and Preclinical Work |
title_fullStr | Discovery and Preclinical Work |
title_full_unstemmed | Discovery and Preclinical Work |
title_short | Discovery and Preclinical Work |
title_sort | discovery and preclinical work |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177020/ http://dx.doi.org/10.1007/978-3-319-02201-7_2 |
work_keys_str_mv | AT mochlyrosendaria discoveryandpreclinicalwork AT grimeskevin discoveryandpreclinicalwork |